Dose reduction and discontinuation of biologic and targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs) in people with axial spondyloarthritis and low disease activity (Protocol)

Jodie C. Avery, Samuel L. Whittle, Renea V. Johnston, Liesl Grobler, Bayden J. McKenzie, Sheila Cyril, Désirée van der Heijde, Rachelle Buchbinder

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. To determine the benefits and harms of dose reduction or discontinuation of biological or targeted synthetic disease-modifying anti-rheumatic drugs in adults with axial spondyloarthritis and low disease activity or remission.

Original languageEnglish
Article numberCD014836
Number of pages18
JournalCochrane Database of Systematic Reviews
Volume2021
Issue number11
DOIs
Publication statusPublished - 22 Nov 2021

Cite this